BASF and the French biotechnology company CYTOO have joined forces in order to develop and test active ingredients that contribute to stimulate the contractility of human fibroblasts (connective tissue cells) in skin care applications and thus improve skin appearance and firmness.
To investigate more deeply these cell features, CYTOO developed FibroScreen, a platform based upon a micro-patterning technology that allows the precise control of cell substrate geometry and stiffness through in innovative method of mecanobiology. The cooperation between BASF and CYTOO will focus on the development of new cell tests, the evaluation of the FibroScreen platform and the identification of new active compounds able to influence the contractility of human fibroblasts for a more durable effect than the mere combination of hyaluronique acid and collagen, which widely used in skin care and anti ageing personal care products.
“For us, this partnership marks an important milestone. It demonstrates that CYTOO is able to build a win-win relationship with a research team of the world’s leading chemical company to quickly advance research and deliver high-value results,” emphasized Luc Selig, CEO of CYTOO.
